Premium
Developing Novel Means to Inhibit Metastasis Through Targeting Tumor Heterogeneity and EMT
Author(s) -
Ford Heide L.,
Kong Deguang,
Neelakantan Deepika,
Zhou Hengbo,
Hughes Connor,
Lewis Michael,
Marugan Juan,
Patnaik Samarijit,
Zhao Rui
Publication year - 2020
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2020.34.s1.00374
Subject(s) - paracrine signalling , metastasis , cancer research , epithelial–mesenchymal transition , cancer cell , breast cancer , crosstalk , cell migration , biology , cancer , cell , receptor , genetics , physics , optics
It is well established that a subset of cells within primary breast cancers can undergo an epithelial to mesenchymal transition (EMT), although the role of EMT in metastasis remains controversial. We previously demonstrated a novel mechanism by which EMT contributes to metastasis, via mediating tumor cell crosstalk. In this seminar, I will discuss how breast cancer cells that have undergone an oncogenic EMT can increase metastasis of neighboring epithelial cancer cells via non‐canonical paracrine‐mediated activation of GLI activity that is dependent on Six1 expression in the EMT cancer cells. I will discuss how VEGF‐C, secreted by breast cancer cells that have undergone an EMT, promotes paracrine‐mediated increases in proliferation, migration, invasion, and metastasis of epithelial breast cancer cells, via non‐canonical activation of GLI‐signaling. Importantly, the aggressive phenotypes imparted by EMT cells on adjacent epithelial cancer cells can be disrupted by either inhibiting VEGF‐C in EMT cells or by knocking down NRP2, which interacts with VEGF‐C, in neighboring epithelial cancer cells both in vitro and in vivo. Interrogation of TCGA and GEO public datasets supports the relevance of this pathway in human breast cancer, as VEGF‐C and GLI pathway genes significantly positively correlate. Our study suggests that the VEGF‐C/NRP2/GLI axis may be a novel and conserved paracrine means by which EMT cells enhance metastasis, and provides potential targets for therapeutic intervention in this heterogeneous disease. In addition, because SIX1 activates VEGF‐C expression which leads to enhancement of metastasis via cell autonomous and non‐cell autonomous means, we have developed an inhibitor that targets SIX1 action and thereby inhibits metastatic disease. We describe results using this inhibitor in cell culture, where it inhibits SIX1 function and EMT, and in animals, where it inhibits metastasis without an effect on primary tumor growth. Support or Funding Information Colorado Cancer Translational Research Accelerator (CCTRA) PI Heide L. Ford, Co‐I Rui ZhaoNCI R01 CA224867 PIs Heide L. Ford and Michael T. Lewis